Stock Events

Stock Events

Definium Therapeutics 

$24.16
930
+$0.39+1.64% Tuesday 19:59

Statistics

Day High
24.28
Day Low
23.47
52W High
26.25
52W Low
6.35
Volume
1,200,368
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q3 2025
Q1 2026
Next
-0.78
-0.68
-0.59
-0.49
Expected EPS
-0.56
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-217.36MNet Income

Analyst Ratings

40.89Average Price Target
The highest estimate is 70.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DFTX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap1.63B
Compass Pathways operates in the psychedelic medicine space, focusing on psilocybin therapy for depression, directly competing with Mind Medicine's psychedelic-based treatments.
AtaiBeckley
ATAI
Mkt Cap1.44B
ATAI Life Sciences is a biotech company with a focus on psychedelic and non-psychedelic compounds for mental health, making it a direct competitor in the psychedelic medicine market.
GH Research
GHRS
Mkt Cap1.45B
GH Research is developing a novel therapeutic approach for mental health disorders using 5-MeO-DMT, competing in the same space as Mind Medicine's psychedelic-based treatments.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness is involved in the development of psychedelic therapies, including psilocybin and MDMA, positioning it as a competitor in the psychedelic medicine industry.
Revive Therapeutics
RVVTF
Mkt Cap10.02M
Revive Therapeutics is exploring the use of psychedelics for the treatment of mental illness and addiction, competing in the same therapeutic space as Mind Medicine.
TripAdvisor
TRIP
Mkt Cap1.44B
Red Light Holland is focused on the production, growth, and sale of a premium brand of magic truffles, entering the broader market of psychedelic substances that Mind Medicine is also targeting.
Noveris Health Sciences
MYCOF
Mkt Cap117.1M
Mydecine Innovations Group is a biotech company focusing on the development of psychedelic therapies, making it a competitor in the emerging field of psychedelic medicine.

About

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Show more...
CEO
Mr. Robert Barrow
Employees
74
Country
United States
ISIN
CA24477V1058

Listings

STU
DE
MMQ0.STU
MU
DE
MMQ0.MU
F
DE
MMQ0.F
XNAS
US
DFTX

0 Comments

Share your thoughts

FAQ

What is Definium Therapeutics stock price today?▼
The current price of DFTX is $24.16 USD — it has increased by +1.64% in the past 24 hours. Watch Definium Therapeutics stock price performance more closely on the chart.
What is Definium Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Definium Therapeutics stocks are traded under the ticker DFTX.
When is the next Definium Therapeutics earnings date?▼
Definium Therapeutics is going to release the next earnings report on August 06, 2026.
What were Definium Therapeutics earnings last quarter?▼
DFTX earnings for the last quarter are -0.71 USD per share, whereas the estimation was -0.49 USD resulting in a -44.27% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Definium Therapeutics revenue for the last year?▼
Definium Therapeutics revenue for the last year amounts to 0 USD.
What is Definium Therapeutics net income for the last year?▼
DFTX net income for the last year is -217.36M USD.
How many employees does Definium Therapeutics have?▼
As of June 17, 2026, the company has 74 employees.
In which sector is Definium Therapeutics located?▼
Definium Therapeutics operates in the Health & Wellness sector.
When did Definium Therapeutics complete a stock split?▼
Definium Therapeutics has not had any recent stock splits.
Where is Definium Therapeutics headquartered?▼
Definium Therapeutics is headquartered in New York, United States.